Circulation Publishes Data Validating Vektor Medical’s Non-invasive Heart Mapping Technology Using Only 12-lead ECG
Retrieved on:
Wednesday, September 7, 2022
Health, FDA, Medical Devices, Clinical Trials, Research, Science, Cardiology, University, ECG, Technology, VMAP, University of Washington Department of Bioengineering, Ventricular tachycardia, Regulation of tobacco by the U.S. Food and Drug Administration, VT, Medical University of South Carolina, Heart, Medicine, University of California, San Diego, Vector, Food, Physician, Department, Department of Medicine – University of Pamplona, Medical school, Electrophysiology, Veterans' affairs, Arrhythmia, Cardiology, PVC, Mills-Peninsula Medical Center, Medical imaging
Vektor Medical , the developer of the worlds first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced Circulation: Arrhythmia and Electrophysiology has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy of its vMap technology.
Key Points:
- Vektor Medical , the developer of the worlds first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced Circulation: Arrhythmia and Electrophysiology has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy of its vMap technology.
- The mapping system uses the information found in a 12-lead ECG and provides physicians with accurate and actionable insights to treat cardiac arrhythmias.
- The median analysis time from ECG data upload into the system and ending with display of the mapping results was 0.8 minutes (IQR: 0.41.4 minutes).
- San Diego-based Vektor Medical, Inc. is the developer of the worlds first FDA-cleared forward-solution arrhythmia mapping technology to rapidly identify arrhythmia source locations using only 12-lead ECG data.